Persistent Systems Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Persistent Launches AI-Powered Generative Molecules and Virtual Screening Solution Powered by NVIDIA".
PERSISTENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Persistent Systems has announced the launch of GenMolVS, a new AI-powered solution for the Healthcare and Life Sciences (HLS) industry, built in collaboration with NVIDIA. The solution uses NVIDIA's full-stack AI platform, including BioNeMo, NeMo Agent Toolkit, Nemotron open models, and NVIDIA AI Enterprise, to enable AI-driven molecular simulations, virtual screening, and candidate prioritization in drug discovery. Persistent says this will help biopharma clients reduce drug discovery timelines from months to days, using simulation-led intelligence to guide real-world laboratory experiments. The company will also leverage NVIDIA's training resources and certification programs to expand its AI engineering capabilities. The solution is part of Persistent's broader push into production-grade Agentic AI applications for the HLS vertical.
This strategic collaboration with NVIDIA strengthens Persistent's positioning in the fast-growing AI-driven drug discovery space and could open new revenue streams in the HLS vertical. While no immediate financial figures were disclosed, the partnership is likely to be viewed positively by the market given NVIDIA's brand association and the high-growth potential of AI in life sciences.